AUS
NZ
UK
CA
USA
IND
Prescient therapeutics limited asx ptx
PTX Solidifies Balance Sheet Further: Announces A$7 million Placement to Support Expanded Pipeline of Innovative Cancer Therapies
August 26, 2020 07:51 PM AEST| By Team Kalkine MediaOn 26 August 2020, Prescient Therapeutics Limited (ASX:PTX) announced that it has received firm commitments to raise A$7,046,084 (before costs) by way of a share placement of 128,110,611 fully paid ordinary shares to professional as well as sophist.....
Only ASX-listed Healthcare Company Developing CAR-T Programs- PTX Collaborates With Peter MacCallum Cancer Centre
August 14, 2020 08:58 PM AEST| By Team Kalkine MediaSummary Prescient collaborating with the world-class cell therapy institute Peter MacCallum Cancer Centre to develop innovative cell therapy technologies, including CAR-T technologies. Prescient will own the resulting IP from the research progr.....
Prescient Therapeutics’ PTX100 Phase 1b Basket Study Progressing Well, Moves to Next Dose Level
August 13, 2020 12:27 PM AEST| By Team Kalkine MediaSummary After demonstrating the safety at a dose of 1,000 mg/m2, Phase 1b study of PTX-100 will proceed to the increased dose of 2,000 mg/m2. Two patients from the first 500 mg/m2 cohort had reported with stable disease or better at the end of .....
_07_24_2026_09_21_10_456585.jpg)
RTG Mining (ASX:RTG) Retreats 12% on Thin Turnover Despite Holding a Positive Annual Return
July 24, 2026 09:21 AM AEST| By Aditi Sarkar• Session turnover was AUD 11,161, indicating limited activity.
Prescient Therapeutics Onboards Internationally Renowned CAR-T Expert Prof Phillip Darcy to Scientific Advisory Board
August 07, 2020 07:20 PM AEST| By Team Kalkine MediaAustralia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed globally renowned cancer and Chimeric Antigen Receptor-T (CAR-T) expert, Professor Phillip Darcy of Peter MacCallum Cancer Centre, to its Scientific .....
Prescient Therapeutics’ Progresses to Next Dose Level in PTX-200 AML Phase 1b Study
August 03, 2020 06:20 PM AEST| By Team Kalkine MediaSummary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose level of 35 mg/m2 PTX-200. Phase 1b study of PTX-200 at a dose of 25 mg/m2 demonstrated no dose-limiting toxicities and therapy was better tole.....
Prescient Therapeutics to Raise A$6.5 million Via SPP to Advance Clinical & Pre-clinical Programs
July 28, 2020 11:31 AM AEST| By Team Kalkine MediaPrescient Therapeutics (ASX:PTX), The ASX-listed biotechnology player developing targeted and personalised medicines for challenging cancers, announced a Share Purchase Plan (SPP) to raise nearly A$6.5 million. The Company intends to use this capit.....
VBX Ltd (ASX:VBX) Retreats 14% With AUD 150,000 in Turnover as Annual Losses Near 18%
July 24, 2026 09:21 AM AEST| By Aditi Sarkar• Session turnover reached AUD 149,793, indicating meaningful investor activity.
Prescient Therapeutics’ Dazzling June Quarter Report, Achieved Significant Milestones
July 23, 2020 11:43 AM AEST| By Team Kalkine MediaSummary In June 2020 quarter, Prescient added new assets in its belt with the most significant milestone of a next-generation immunotherapy platform ‘OmniCAR’. Prescient onboarded former Juno Executive Dr Allen Ebens, having a vast .....
Remarkable! Assets of Prescient Selected for COVID-19 Antiviral Testing Program by Doherty Institute
July 22, 2020 12:49 PM AEST| By Team Kalkine MediaClinical stage oncology company Prescient Therapeutics Limited (ASX:PTX) notified that two of its assets had been selected as Group 1 priority candidates for a COVID-19 antiviral testing program by Doherty Institute in Melbourne. Both assets of PTX.....
Get Acquainted with Prescient Therapeutics’ Next Generation Immunotherapy Platform
June 19, 2020 11:39 AM AEST| By Team Kalkine MediaPrescient Therapeutics Limited (ASX:PTX) is a clinical-stage oncology company developing personalised medicine approaches to cancer, including cellular as well as targeted therapies. The targeted therapies include two drug candidates, PTX-200 and P.....
West Wits Mining (ASX:WWI) Pulls Back 13% But Shareholders Still Ahead 61% on the Year
July 24, 2026 09:21 AM AEST| By Aditi Sarkar• Session turnover reached AUD 483,798, reflecting high investor engagement.
Another Golden Feather in Prescient’s Hat, PTX-200 Receives Two US Patents
June 17, 2020 05:11 PM AEST| By Team Kalkine MediaWell-known for developing breakthrough targeted and personalised medicines approaches to treat cancer, Prescient Therapeutics Limited (ASX:PTX) has been gaining attention on the back of its recent achievements. Building on this momentum, on 17 June.....
Prescient Onboards Former Juno Executive Dr Allen Ebens, Stock Zooms Up 25%
June 04, 2020 12:22 PM AEST| By Team Kalkine MediaSummary Dr Allen Ebens was formerly a key executive in Juno Therapeutics, a CAR-T pioneer company. His experience and expertise would be valuable for PTX in developing cancer therapy platform. Vast experience of over 24 years in drug developmen.....
Impressive! Prescient Obtains Key Licenses for Next Generation Immunotherapy Platform
May 28, 2020 11:45 AM AEST| By Team Kalkine MediaSummary Prescient obtains two key licenses from world immunotherapy leader, University of Pennsylvania and Oxford University to create a revolutionary cancer therapy platform called “OmniCAR”. OmniCAR platform would allow extraordin.....
Why Is AUB Group (ASX:AUB) in Focus Ahead of Its FY26 Results?
July 24, 2026 09:21 AM AEST| By Aditi SarkarAUB Group Limited (ASX:AUB) has remained in focus following a series of governance and corporate announcements ahead of its FY26 financial results. The insurance broking and underwriting group has continued to update the market on board changes, shareholder movements and its upcoming reporting schedule. …
Prescient Now the Outright Owner of IP Resulting from CAR-T Collaboration
May 11, 2020 06:02 PM AEST| By Team Kalkine MediaASX-listed Australia based clinical-stage oncology player Prescient Therapeutics Limited (ASX:PTX) is engaged in the development of new drugs that demonstrate significant promise as potential innovative therapies for the treatment of challenging canc...
Prescient’s Clinical Trials for PTX100 Progressing Well; Moves to Next Stage
April 23, 2020 12:43 PM AEST| By Team Kalkine MediaClinical trials are being shuttered in increasing numbers in Australia because of the challenges posed by COVID-19; however, one clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) continues to march ahead. The Company has a str...
Prescient Reports March 2020 Quarterly Update; Cash Reserves at $8.2 Million
April 17, 2020 01:14 PM AEST| By Team Kalkine MediaAustralian based clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX), recently reported operating highlights and financial outcomes for the March quarter 2020. The Company is engaged in the development of new drugs that demonstr...
Image Resources (ASX:IMA) Drops 14% as Stock Confronts a 76% Collapse Over 12 Months
July 24, 2026 09:20 AM AEST| By Aditi Sarkar• Session turnover was AUD 31,451.
Prescient Therapeutics’ Operations Remain Unscathed by COVID-19 Pandemic
April 08, 2020 12:57 PM AEST| By Team Kalkine MediaThe Coronavirus has become a health threat across the globe and as per World Health Organization (WHO) until now this pandemic has resulted in over 72,744 deaths and infected more than 1,282,931 worldwide in just a few months (8 April 2020, 1:57 GMT,...
Prescient Therapeutics- A Shining Star Amidst Cancer Space
March 27, 2020 01:58 PM AEDT| By Team Kalkine Media1 in 6 deaths is due to cancer As per World Health Organization, Cancer is the 2nd major cause of death globally, and is responsible for an ~9.6 million deaths in 2018. Worldwide, about one in six deaths is owing to cancer. Demand for effective can...
Prescient Therapeutics Update on Half Year Financials: Positive Clinical Development Continued
March 02, 2020 12:33 PM AEDT| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company which is into small molecule drug development focused on new drugs for the treatment of a range of cancers that have become resistant to front line chemo...
Investigator Silver (ASX:IVR) Gives Back 13% in Heavy Trade Despite Holding a 44% Annual Gain
July 24, 2026 09:20 AM AEST| By Aditi Sarkar• Session turnover reached AUD 677,002 — the highest of the peer group by a wide margin.
Mapping Prescient’s PTX-200 Progress
February 19, 2020 02:14 PM AEDT| By Team Kalkine MediaKnown for developing breakthrough personalised medicines using an approach to address specific mutations that drive cancer, thereby providing resistance to front line chemotherapy, Prescient Therapeutics Limited (ASX: PTX) has been gaining...
Prescient Therapeutics December 2019 Quarterly Update Unveiling Strong Clinical Progress
February 03, 2020 10:29 AM AEDT| By Team Kalkine MediaPrescient Therapeutics Limited (ASX: PTX), an Australian based clinical-stage Oncology company, dedicated towards the treatment of an array of challenging cancers with significant unmet need has recently reported operating highlights and financi...
Advertise your brand on Kalkine Media